Zhenzhen Xu

6PUBLICATIONS
21CO-AUTHORS
Molecular medicineMolecular targetsLiquid biopsiesCancer geneticsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jun 04, 2025
FDA Approval Summary: Idecabtagene Vicleucel for the Treatment of Triple-Class-Exposed, Relapsed or Refractory Multiple Myeloma.

Poornima Sharma, Xue Lin, Zhenzhen Xu

|Dec 20, 2024
FDA Approval Summary: Nadofaragene Firadenovec-vncg for Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer.

Laronna Colbert, Yuxia Jia, Anurag Sharma

|Feb 07, 2024
FDA Approval Summary: Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma.

Mona Elmacken, Helkha Peredo-Pinto, Cong Wang

|Jul 05, 2023
FDA Approval Summary: Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma.

Poornima Sharma, Yvette L Kasamon, Xue Lin

|Sep 18, 2020
Design for immuno-oncology clinical trials enrolling both responders and nonresponders.

Zhenzhen Xu, Bin Zhu, Yongsoek Park

|Sep 12, 2018
Designing cancer immunotherapy trials with random treatment time-lag effect.

Zhenzhen Xu, Yongsoek Park, Boguang Zhen

Pageof 1

Frequent Collaborators

3 joint publications

Marc R Theoret

2 joint publications

Poornima Sharma

2 joint publications

Yvette L Kasamon

2 joint publications

Xue Lin